The backtest results for VALN show mixed performance following earnings beats, with a 50% win rate at both 3 and 10 days, but a 0% win rate at 30 days. Short-term returns are modestly positive, peaking at 3.69% over 10 days, while the 30-day return turns negative at -7.51%. This suggests initial optimism fades over a longer horizon. The maximum return observed was 12.48% on day 54, indicating potential for delayed gains. Investors should consider short-term positions post-earnings beat but remain cautious about holding long term due to negative 30-day outcomes.

backtest_data

The backtest results show that VALN has a 62.5% win rate at 3 and 30 days post-earnings miss, but the average returns are slightly negative over 30 days, with a -0.86% return. This indicates that while the stock often recovers or gains shortly after the event, the overall impact tends to be mildly adverse in the medium term. Investors should be cautious about holding VALN long-term after an earnings miss, as the data suggests limited positive momentum and potential downside risk.

The backtest results show that the Biotechnology Industry experienced a slight negative impact following earnings beats, with a maximum return of only 0.50% occurring 15 days after the event. This indicates that despite positive earnings surprises, the sector did not generate significant positive returns in the observed period.

The analysis suggests that earnings beats in this industry may not strongly translate into immediate or substantial stock price gains, possibly due to other overriding market factors or sector-specific challenges.

Investors should be cautious about expecting strong positive price reactions solely based on earnings beats in the Biotechnology Industry.

The backtest results show that earnings misses in the Biotechnology Industry had no significant impact, with a maximum return of only 0.36% occurring three days after the event. This negligible effect suggests that the industry’s stock prices are largely unaffected by earnings misses over the tested period.

The analysis indicates that investors should not expect meaningful price movements in the Biotechnology sector following earnings disappointments, reflecting market resilience or other overriding factors.

Therefore, investment strategies based on earnings misses in this industry may not yield substantial opportunities or risks.

Backtest VALN Release Earning Report

Find all upcoming company earnings reports scheduled for mar 01 2026. Get details on which companies are reporting and their expected results.

Calendar